Unknown.png
Entera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019
August 15, 2019 07:00 ET | Entera Bio
JERUSALEM, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before...
Unknown.png
Entera Bio Appoints Adam Gridley as Chief Executive Officer
August 05, 2019 08:00 ET | Entera Bio
JERUSALEM, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip...
Unknown.png
Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH
July 02, 2019 07:00 ET | Entera Bio
JERUSALEM, July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH...
Unknown.png
Entera Bio Reports First Quarter 2019 Financial Results and Operating Update
June 27, 2019 07:00 ET | Entera Bio
Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing,...
Unknown.png
Entera Bio Reports 2018 Annual Financial Results and Operating Update
March 28, 2019 07:00 ET | Entera Bio
Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosisEntered into research collaboration and license agreement with Amgen, potential for up to $270...
Unknown.png
Entera Bio Announces 20-F Filing
March 28, 2019 07:00 ET | Entera Bio
JERUSALEM, March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S....
Unknown.png
Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28
March 27, 2019 11:02 ET | Entera Bio
JERUSALEM, March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the...
Unknown.png
Entera Bio Announces a Transition in the Chief Financial Officer Position
March 07, 2019 07:00 ET | Entera Bio
JERUSALEM, March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable...
Unknown.png
Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis
January 31, 2019 08:00 ET | Entera Bio
JERUSALEM, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss...
Unknown.png
Entera Bio Reports Third Quarter 2018 Financial Results and Operating Update
January 22, 2019 08:00 ET | Entera Bio
Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial salesMet with FDA in late November 2018...